Other Mutations: CD70

NCT02830724: Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

NCT02830724
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: CD70
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 70 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: Tumors must express CD70
Exclusions: Patients with 4 or more symptomatic brain metastases that are more than 1 cm in diameter
https://ClinicalTrials.gov/show/NCT02830724

Up ↑